Metabolism in chronic graft‑versus‑host disease with lung damage
Metabolomics of cGVHD
['FUNDING_P01'] · DANA-FARBER CANCER INST · NIH-11174484
Seeing whether targeting the energy use of immune cells and lung cells can help people with chronic graft‑versus‑host disease, including those with transplant‑related lung problems.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11174484 on ClinicalTrials.gov |
What this research studies
The team is studying how immune cells in germinal centers and damaged lung progenitor cells use energy and handle oxidative stress in chronic GVHD with bronchiolitis obliterans. They use metabolomics (measuring small molecules), laboratory disease models, and cellular studies to find metabolic weaknesses in pathogenic T and B cells while preserving regulatory cells and lung repair cells. Promising drugs or drug combinations identified in the lab will be prioritized for clinical testing to help people with persistent, treatment‑resistant cGVHD and lung complications.
Who could benefit from this research
Good fit: Ideal candidates are people who had an allogeneic stem cell transplant and now have chronic GVHD, especially those with bronchiolitis obliterans or disease that does not respond to first‑line steroids.
Not a fit: People without cGVHD, with lung disease unrelated to transplant, or whose cGVHD is well controlled with standard therapy are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could lead to new therapies that reduce organ damage, improve lung function, and increase survival for people with chronic GVHD.
How similar studies have performed: Prior preclinical work from this group led to clinical trials and two FDA‑approved therapies for cGVHD, though focusing specifically on germinal center and lung stem‑cell metabolism is a newer strategy.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BLAZAR, BRUCE R — DANA-FARBER CANCER INST
- Study coordinator: BLAZAR, BRUCE R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Adult-Onset Diabetes Mellitus